We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We may also share information about your use of our site with our social media, advertising and analytics partners. Read more about our Privacy Policy.

I got it!


We urge the @EU_Commission to #revise the #CBHD & address shortcomings that include long approval times, fragmented payment/reimbursements, limited access to clinical trials, disjointed implementation: all hindering #patientaccess to #innovativetherapies! https://t.co/7gcpDjBNY9 https://t.co/SKGKjfnqXX

13 May 2022 / Source: @EuropaBio

Other News in Science